The promise and potential pitfalls of chimeric antigen receptors.

[1]  W. Kast,et al.  Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition , 2009, Cancer Immunology, Immunotherapy.

[2]  Michel Sadelain,et al.  Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy , 2009, Journal of immunotherapy.

[3]  M. Sadelain,et al.  Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras. , 2008, The Journal of clinical investigation.

[4]  B. Seliger,et al.  Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas , 2008, Proceedings of the National Academy of Sciences.

[5]  Hao Liu,et al.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.

[6]  Jinjuan Wang,et al.  Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. , 2008, Blood.

[7]  M. Smyth,et al.  Adoptive Transfer of Gene-Modified Primary NK Cells Can Specifically Inhibit Tumor Progression In Vivo1 , 2008, The Journal of Immunology.

[8]  Michel Sadelain,et al.  Monitoring the Efficacy of Adoptively Transferred Prostate Cancer–Targeted Human T Lymphocytes with PET and Bioluminescence Imaging , 2008, Journal of Nuclear Medicine.

[9]  D. Gilham,et al.  The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B‐cell lymphoma , 2008, British journal of haematology.

[10]  R. Jacobs,et al.  Imaging Immune Response In vivo: Cytolytic Action of Genetically Altered T Cells Directed to Glioblastoma Multiforme , 2008, Clinical Cancer Research.

[11]  P. Greenberg,et al.  Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane1 , 2008, The Journal of Immunology.

[12]  E. Shpall,et al.  Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. , 2008, Cancer research.

[13]  B. Seliger.  Molecular mechanisms of MHC class I abnormalities and APM components in human tumors , 2008, Cancer Immunology, Immunotherapy.

[14]  Sylvain Julien,et al.  Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor1 , 2008, The Journal of Immunology.

[15]  Michel Sadelain,et al.  Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors , 2008, Nature Biotechnology.

[16]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[17]  J. Wagner,et al.  Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  W. Wels,et al.  Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells , 2008, Cancer Immunology, Immunotherapy.

[19]  Mike Gough,et al.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.

[20]  Bin Liang,et al.  Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3ζ recombinant gene , 2008, Leukemia & lymphoma.

[21]  Tong Zhang,et al.  Immunotherapy with Chimeric NKG2D Receptors Leads to Long-Term Tumor-Free Survival and Development of Host Antitumor Immunity in Murine Ovarian Cancer12 , 2008, The Journal of Immunology.

[22]  M. Sadelain,et al.  T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection , 2007, Nature Medicine.

[23]  M. Kalos,et al.  A First-In-Human Clinical Trial of Adoptive Therapy Using CD19-Specific Chimeric Antigen Receptor Re-Directed T-Cells for Recurrent/Refractory Follicular Lymphoma. , 2007 .

[24]  Tong Zhang,et al.  Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. , 2007, Cancer research.

[25]  S. Canevari,et al.  Redirected Activity of Human Antitumor Chimeric Immune Receptors is Governed by Antigen and Receptor Expression Levels and Affinity of Interaction , 2007, Journal of immunotherapy.

[26]  M. Stastny,et al.  Medulloblastomas Expressing IL13Rα2 are Targets for IL13-zetakine+ Cytolytic T Cells , 2007, Journal of pediatric hematology/oncology.

[27]  David M Kranz,et al.  Display, engineering, and applications of antigen-specific T cell receptors. , 2007, Biomolecular engineering.

[28]  H. Heslop,et al.  Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. , 2007, Blood.

[29]  S. Larson,et al.  Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts , 2007, Clinical Cancer Research.

[30]  D. Campana,et al.  Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal. , 2007, Experimental hematology.

[31]  C. Rooney,et al.  Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function. , 2007, Cancer research.

[32]  S. Riddell,et al.  Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. , 2007, Human gene therapy.

[33]  Takako Kato,et al.  Protection from Lethal Infection by Adoptive Transfer of CD8 T Cells Genetically Engineered to Express Virus-Specific Innate Immune Receptor1 , 2007, The Journal of Immunology.

[34]  E. Rieber,et al.  Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T‐cells , 2007, The Prostate.

[35]  R. Gilbertson,et al.  Regression of experimental medulloblastoma following transfer of HER2-specific T cells. , 2007, Cancer research.

[36]  K. Roby,et al.  Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. , 2007, Cancer research.

[37]  S. Sleijfer,et al.  Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo , 2007, Cancer Immunology, Immunotherapy.

[38]  P. Hwu,et al.  Antitumor activity of dual-specific T cells and influenza virus , 2007, Cancer Gene Therapy.

[39]  M. Slovak,et al.  Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  H. Heslop,et al.  T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. , 2006, Blood.

[41]  M. Smyth,et al.  Adoptive Transfer of Chimeric Fc ε RI Receptor Gene-Modified Human T Cells for Cancer Immunotherapy , 2006 .

[42]  David D. Smith,et al.  CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. , 2006, Cancer research.

[43]  Gang Wang,et al.  A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.

[44]  P. Stern,et al.  Combination of Vaccination and Chimeric Receptor Expressing T Cells Provides Improved Active Therapy of Tumors1 , 2006, The Journal of Immunology.

[45]  M. Brenner,et al.  Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells , 2006, Leukemia.

[46]  A. Biondi,et al.  Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. , 2006, Experimental hematology.

[47]  M. Kuroki,et al.  Antitumor activity of chimeric immunoreceptor gene‐modified Tc1 and Th1 cells against autologous carcinoembryonic antigen‐expressing colon cancer cells , 2006, Cancer science.

[48]  E. Pamer,et al.  Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation , 2006, Nature Medicine.

[49]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  S. Rosenberg,et al.  Adoptive immunotherapy for cancer: building on success , 2006, Nature Reviews Immunology.

[51]  D. Gilham,et al.  Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo , 2006, Gene Therapy.

[52]  A. Scott,et al.  Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[53]  H. Heslop,et al.  A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[54]  J. Trapani,et al.  Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. , 2005, Blood.

[55]  Michel Sadelain,et al.  Targeted elimination of prostate cancer by genetically directed human T lymphocytes. , 2005, Cancer research.

[56]  D. Campana,et al.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. , 2005, Blood.

[57]  R. Debets,et al.  T Cell Retargeting with MHC Class I-Restricted Antibodies: The CD28 Costimulatory Domain Enhances Antigen-Specific Cytotoxicity and Cytokine Production1 , 2005, The Journal of Immunology.

[58]  P. Stern,et al.  The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors: Evaluation of Four Different scFvs and Antigens , 2005, Journal of immunotherapy.

[59]  David D. Smith,et al.  Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. , 2005, Blood.

[60]  S. Forman,et al.  Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells , 2004, Cancer Research.

[61]  A. Boynton,et al.  Anti‐prostate specific membrane antigen designer T cells for prostate cancer therapy , 2004, The Prostate.

[62]  M. Smyth,et al.  Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. , 2004, Human gene therapy.

[63]  M. Jensen,et al.  Genetic engineering of cytolytic T lymphocytes for adoptive T‐cell therapy of neuroblastoma , 2004, The journal of gene medicine.

[64]  J. Trapani,et al.  A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells , 2004, Cancer Gene Therapy.

[65]  D. Campana,et al.  Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia , 2004, Leukemia.

[66]  S. Riddell,et al.  Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[67]  M. Kuroki,et al.  Generation and Targeting of Human Tumor-Specific Tc1 and Th1 Cells Transduced with a Lentivirus Containing a Chimeric Immunoglobulin T-Cell Receptor , 2004, Cancer Research.

[68]  A. Lawson,et al.  Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ Chain , 2004, The Journal of Immunology.

[69]  Z. Eshhar,et al.  Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. , 2003, Cancer research.

[70]  J. Blattman,et al.  Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. , 2003, Cancer Cell.

[71]  P. Nguyen,et al.  Antigen-specific targeting of CD8+ T cells with receptor-modified T lymphocytes , 2003, Gene Therapy.

[72]  S. Larson,et al.  Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.

[73]  J. Trapani,et al.  Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-Chain Antibody Receptors Codelivering CD28 Costimulation1 , 2002, The Journal of Immunology.

[74]  P. Hwu,et al.  Dual-specific T cells combine proliferation and antitumor activity , 2002, Nature Biotechnology.

[75]  J. Trapani,et al.  Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. , 2002, Blood.

[76]  Sven Becker,et al.  Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. , 2002, Blood.

[77]  L. Ren-Heidenreich,et al.  Comparison of the TCR ζ-chain with the FcR γ-chain in chimeric TCR constructs for T cell activation and apoptosis , 2002, Cancer Immunology, Immunotherapy.

[78]  R. Mulligan,et al.  Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[79]  C. Rooney,et al.  Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. , 2002, Blood.

[80]  B. Seliger,et al.  Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated Into One Combined CD28/CD3ζ Signaling Receptor Molecule1 , 2001, The Journal of Immunology.

[81]  R. Flavell,et al.  Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. , 2001, Blood.

[82]  H. Abken,et al.  CD4+ T Cells Engrafted with a Recombinant Immunoreceptor Efficiently Lyse Target Cells in a MHC Antigen- and Fas-Independent Fashion1 , 2001, The Journal of Immunology.

[83]  J. Muche,et al.  T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30+ cutaneous lymphoma cells , 2001, Gene Therapy.

[84]  B. Seliger,et al.  T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. , 2001, Cancer research.

[85]  Mark J. Smyth,et al.  Redirecting Mouse CTL Against Colon Carcinoma: Superior Signaling Efficacy of Single-Chain Variable Domain Chimeras Containing TCR-ζ vs FcεRI-γ1 , 2001, The Journal of Immunology.

[86]  P. Hwu,et al.  Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature. , 2000, Human gene therapy.

[87]  S. Rosenberg,et al.  Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. , 2000, Human gene therapy.

[88]  E. Beecham,et al.  Coupling CD28 Co-Stimulation to Immunoglobulin T-Cell Receptor Molecules: The Dynamics of T-Cell Proliferation and Death , 2000, Journal of immunotherapy.

[89]  J. Mcarthur,et al.  Anti-Tumor CC49-ζ CD4 T Cells Possess Both Cytolytic and Helper Functions , 2000 .

[90]  V. Diehl,et al.  An entirely humanized CD3 ζ‐chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen–positive tumor cells , 2000, International journal of cancer.

[91]  C. Yun,et al.  Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. , 2000, Neoplasia.

[92]  E. Beecham,et al.  Dynamics of Tumor Cell Killing by Human T Lymphocytes Armed With an Anti-Carcinoembryonic Antigen Chimeric Immunoglobulin T-Cell Receptor , 2000, Journal of immunotherapy.

[93]  J. Trapani,et al.  Redirected Perforin-Dependent Lysis of Colon Carcinoma by Ex Vivo Genetically Engineered CTL1 , 2000, The Journal of Immunology.

[94]  C. Yun,et al.  Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[95]  N. Bander,et al.  Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. , 1999, Neoplasia.

[96]  P. Hand,et al.  Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. , 1999, Human gene therapy.

[97]  S. Canevari,et al.  Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. , 1998, Cancer gene therapy.

[98]  M. Sadelain,et al.  Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes , 1998, The Journal of experimental medicine.

[99]  B. V. van Krimpen,et al.  Chimeric scFv/γ receptor‐mediated T‐cell lysis of tumor cells is coregulated by adhesion and accessory molecules , 1998, International journal of cancer.

[100]  K. Zsebo,et al.  Antigen-Specific Cytolysis by Neutrophils and NK Cells Expressing Chimeric Immune Receptors Bearing ζ or γ Signaling Domains , 1998, The Journal of Immunology.

[101]  S. Rosenberg,et al.  A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-γ chain chimeric receptor gene recognizing a human ovarian cancer antigen , 1998, Nature Medicine.

[102]  B. Groner,et al.  Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. , 1997, Journal of immunology.

[103]  M. Weijtens,et al.  Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. , 1996, Journal of immunology.

[104]  B. Groner,et al.  Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[105]  S. Rosenberg,et al.  In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. , 1995, Cancer research.

[106]  Z. Eshhar,et al.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[107]  M. Amiot,et al.  Sequence requirements for induction of cytolysis by the T cell antigen Fc receptor ζ chain , 1992, Cell.

[108]  Arthur Weiss,et al.  The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways , 1991, Cell.

[109]  G. McNamara,et al.  Transgene-enforced co-stimulation of CD4+ T cells leads to enhanced and sustained anti-tumor effector functioning. , 2007, Cytotherapy.

[110]  U. Ritz,et al.  Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation , 2006, International journal of cancer.

[111]  H. Müller-Hermelink,et al.  Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor. , 2006, Cancer research.

[112]  Z. Eshhar,et al.  The T-body approach: potential for cancer immunotherapy , 2004, Springer Seminars in Immunopathology.

[113]  G. Bauerschmitz,et al.  In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells , 2004, Cancer Immunology, Immunotherapy.

[114]  E. Rummeny,et al.  In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging , 2004, European Radiology.

[115]  Michel Sadelain,et al.  Targeting tumours with genetically enhanced T lymphocytes , 2003, Nature Reviews Cancer.

[116]  A. Wu,et al.  Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. , 2003, Cytotherapy.

[117]  Michel Sadelain,et al.  Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor , 2002, Nature Biotechnology.

[118]  G. Hayman,et al.  Specific targeting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors. , 2000, Human gene therapy.

[119]  J. Lebkowski,et al.  Ligand-mediated cytolysis of tumor cells: Use of heregulin-ζ chimeras to redirect cytotoxic T lymphocytes , 2000, Cancer Gene Therapy.

[120]  P. Hwu,et al.  Recognition of human colon cancer by T cells transduced with a chimeric receptor gene , 2000, Cancer Gene Therapy.

[121]  M. Weijtens,et al.  Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production , 2000, Gene Therapy.